Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J; PLESS Study Group.

Urology. 2003 Mar;61(3):579-84.

PMID:
12639651
2.
4.
5.

5alpha-reductase inhibitors: what role should they play?

Kaplan SA.

Urology. 2001 Dec;58(6 Suppl 1):65-70; discussion 70. Review.

PMID:
11750255
6.

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.

Logan YT, Belgeri MT.

Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. Review.

PMID:
16129387
8.

Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.

Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, Sforza A, Mannucci E, Maggi M.

Andrology. 2017 Jul;5(4):671-678. doi: 10.1111/andr.12353. Epub 2017 Apr 28. Review.

PMID:
28453908
9.
10.
11.

[Finasteride in the treatment of benign prostatic hypertrophy].

Ekman P.

J Urol (Paris). 1993;99(6):299-302. Review. French.

PMID:
7516372
12.

Benign prostatic hyperplasia progression and its impact on treatment.

Djavan B, Waldert M, Ghawidel C, Marberger M.

Curr Opin Urol. 2004 Jan;14(1):45-50. Review.

PMID:
15091050
13.

Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.

Ekman P.

Arch Esp Urol. 1994 Nov;47(9):883-7; discussion 887-8. Review.

PMID:
7530944
14.

Finasteride for prostatic disease: an updated and comprehensive review.

De Nunzio C, Miano R, Trucchi A, Finazzi Agrò E, Tubaro A.

Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1561-8. doi: 10.1517/17425250802587058 . Review.

PMID:
19040331
15.

Prostate cancer prevention and finasteride.

D'Amico AV, Barry MJ.

J Urol. 2006 Nov;176(5):2010-2; discussion 2012-3. Review.

PMID:
17070238
16.

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.

J Clin Oncol. 2005 Mar 20;23(9):1911-20. Review.

PMID:
15774783
17.
18.

Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.

Dolder CR.

Ann Pharmacother. 2006 Apr;40(4):658-65. Epub 2006 Mar 28. Review.

PMID:
16569804
19.

[Pharmacologic treatment of benign prostatic hyperplasia].

Romics I.

Orv Hetil. 2003 Sep 14;144(37):1809-14. Review. Hungarian.

PMID:
14596018

Supplemental Content

Support Center